D60.9
Acquired pure red cell aplasia, unspecified
Clinical Classification Guidelines
Medical Intelligence & Overview
Acquired pure red cell aplasia (PRCA) is a rare blood disorder characterized by the rapid decline of red blood cell production in the bone marrow, leading to anemia. The term 'acquired' indicates that this condition develops during a person's life, as opposed to being inherited. When the cause isn’t specifically identified, the condition is classified as 'unspecified' under ICD-10 code D60.9. Recognizing and understanding PRCA is crucial for proper diagnosis and management, although it remains a complex condition often requiring specialized medical care.
Causes & Symptoms
Clinical Causes: Autoimmune disorders where the body's immune system mistakenly attacks red blood cell precursors Certain infections, such as parvovirus B19, which can temporarily suppress red blood cell production Exposure to certain medications that affect bone marrow function Hematologic malignancies or cancers that involve the bone marrow Secondary to other medical conditions such as thymomas or chronic lymphocytic leukemia Idiopathic cases where the precise cause cannot be determined
Key Symptoms: Severe fatigue and weakness due to anemia Pale skin, especially in the face and inner eyelids Shortness of breath, especially upon exertion Dizziness or lightheadedness Rapid heartbeat or palpitations In cases involving immune-mediated causes, there might be signs of other autoimmune conditions In rare instances, no symptoms are present and the condition is detected through blood tests during evaluation for other issues
Diagnostic & Treatment
Diagnosis Path: Diagnosing acquired pure red cell aplasia involves several steps. Blood tests typically reveal a low red blood cell count and sometimes a low reticulocyte count, indicating decreased red blood cell production. A bone marrow biopsy can confirm the diagnosis by showing a marked reduction or absence of erythroid precursors (the cells responsible for red blood cell development). Additional tests might include assessments for markers of immune activity, infections, or other underlying conditions that could cause the condition. Medical providers may also perform tests to rule out other types of anemia or marrow disorders.
Treatment Protocols: Treatment approaches focus on addressing the underlying cause, restoring red blood cell production, and suppressing abnormal immune responses if they are involved. Common options include: - Immunosuppressive therapy to reduce immune system attack on red blood cell precursors - Corticosteroids to manage immune activity - Cyclosporine or other immunosuppressive agents for severe cases - Blood transfusions may be used temporarily to manage severe anemia - Treating underlying infections or removing offending medications - In cases related to thymomas or other specific conditions, surgical intervention may be necessary In some instances, patients might recover spontaneously, but ongoing medical supervision is essential to prevent complications and monitor blood cell counts.
Clinical Advice & FAQs
Billing Guidance
Is D60.9 a billable ICD-10 code?
Yes, D60.9 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D60.9?
Clinical documentation must specify the nature of Acquired pure red cell aplasia, unspecified and any associated comorbidities for accurate reporting.
Cite this Clinical Reference